NCT05940324View on ClinicalTrials.gov

Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

February 24, 2024

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2028

Conditions
Obsessive-Compulsive Disorder
Interventions
DRUG

Ketamine

Ketamine is an FDA-approved dissociative anesthetic.

DRUG

Naltrexone Pill

Naltrexone is an oral opioid antagonist approved by the Food and Drug Administration (FDA) to treat both alcohol use disorder (AUD) and opioid use disorder (OUD)

OTHER

Placebo pill

An oral inactive placebo pill will be administered to preserve the blinded nature of the study.

Trial Locations (1)

94305

RECRUITING

Department of Psychiatry & Behavioral Sciences, Stanford

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Stanford University

OTHER